Cargando…

Pleiotropic Effects of Exosomes as a Therapy for Stroke Recovery

Stroke is the leading cause of disability, and stroke survivors suffer from long-term sequelae even after receiving recombinant tissue plasminogen activator therapy and endovascular intracranial thrombectomy. Increasing evidence suggests that exosomes, nano-sized extracellular membrane vesicles, enh...

Descripción completa

Detalles Bibliográficos
Autores principales: Ueno, Yuji, Hira, Kenichiro, Miyamoto, Nobukazu, Kijima, Chikage, Inaba, Toshiki, Hattori, Nobutaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555640/
https://www.ncbi.nlm.nih.gov/pubmed/32962207
http://dx.doi.org/10.3390/ijms21186894
_version_ 1783594054539280384
author Ueno, Yuji
Hira, Kenichiro
Miyamoto, Nobukazu
Kijima, Chikage
Inaba, Toshiki
Hattori, Nobutaka
author_facet Ueno, Yuji
Hira, Kenichiro
Miyamoto, Nobukazu
Kijima, Chikage
Inaba, Toshiki
Hattori, Nobutaka
author_sort Ueno, Yuji
collection PubMed
description Stroke is the leading cause of disability, and stroke survivors suffer from long-term sequelae even after receiving recombinant tissue plasminogen activator therapy and endovascular intracranial thrombectomy. Increasing evidence suggests that exosomes, nano-sized extracellular membrane vesicles, enhance neurogenesis, angiogenesis, and axonal outgrowth, all the while suppressing inflammatory reactions, thereby enhancing functional recovery after stroke. A systematic literature review to study the association of stroke recovery with exosome therapy was carried out, analyzing species, stroke model, source of exosomes, behavioral analyses, and outcome data, as well as molecular mechanisms. Thirteen studies were included in the present systematic review. In the majority of studies, exosomes derived from mesenchymal stromal cells or stem cells were administered intravenously within 24 h after transient middle cerebral artery occlusion, showing a significant improvement of neurological severity and motor functions. Specific microRNAs and molecules were identified by mechanistic investigations, and their amplification was shown to further enhance therapeutic effects, including neurogenesis, angiogenesis, axonal outgrowth, and synaptogenesis. Overall, this review addresses the current advances in exosome therapy for stroke recovery in preclinical studies, which can hopefully be preparatory steps for the future development of clinical trials involving stroke survivors to improve functional outcomes.
format Online
Article
Text
id pubmed-7555640
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75556402020-10-19 Pleiotropic Effects of Exosomes as a Therapy for Stroke Recovery Ueno, Yuji Hira, Kenichiro Miyamoto, Nobukazu Kijima, Chikage Inaba, Toshiki Hattori, Nobutaka Int J Mol Sci Review Stroke is the leading cause of disability, and stroke survivors suffer from long-term sequelae even after receiving recombinant tissue plasminogen activator therapy and endovascular intracranial thrombectomy. Increasing evidence suggests that exosomes, nano-sized extracellular membrane vesicles, enhance neurogenesis, angiogenesis, and axonal outgrowth, all the while suppressing inflammatory reactions, thereby enhancing functional recovery after stroke. A systematic literature review to study the association of stroke recovery with exosome therapy was carried out, analyzing species, stroke model, source of exosomes, behavioral analyses, and outcome data, as well as molecular mechanisms. Thirteen studies were included in the present systematic review. In the majority of studies, exosomes derived from mesenchymal stromal cells or stem cells were administered intravenously within 24 h after transient middle cerebral artery occlusion, showing a significant improvement of neurological severity and motor functions. Specific microRNAs and molecules were identified by mechanistic investigations, and their amplification was shown to further enhance therapeutic effects, including neurogenesis, angiogenesis, axonal outgrowth, and synaptogenesis. Overall, this review addresses the current advances in exosome therapy for stroke recovery in preclinical studies, which can hopefully be preparatory steps for the future development of clinical trials involving stroke survivors to improve functional outcomes. MDPI 2020-09-20 /pmc/articles/PMC7555640/ /pubmed/32962207 http://dx.doi.org/10.3390/ijms21186894 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Ueno, Yuji
Hira, Kenichiro
Miyamoto, Nobukazu
Kijima, Chikage
Inaba, Toshiki
Hattori, Nobutaka
Pleiotropic Effects of Exosomes as a Therapy for Stroke Recovery
title Pleiotropic Effects of Exosomes as a Therapy for Stroke Recovery
title_full Pleiotropic Effects of Exosomes as a Therapy for Stroke Recovery
title_fullStr Pleiotropic Effects of Exosomes as a Therapy for Stroke Recovery
title_full_unstemmed Pleiotropic Effects of Exosomes as a Therapy for Stroke Recovery
title_short Pleiotropic Effects of Exosomes as a Therapy for Stroke Recovery
title_sort pleiotropic effects of exosomes as a therapy for stroke recovery
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555640/
https://www.ncbi.nlm.nih.gov/pubmed/32962207
http://dx.doi.org/10.3390/ijms21186894
work_keys_str_mv AT uenoyuji pleiotropiceffectsofexosomesasatherapyforstrokerecovery
AT hirakenichiro pleiotropiceffectsofexosomesasatherapyforstrokerecovery
AT miyamotonobukazu pleiotropiceffectsofexosomesasatherapyforstrokerecovery
AT kijimachikage pleiotropiceffectsofexosomesasatherapyforstrokerecovery
AT inabatoshiki pleiotropiceffectsofexosomesasatherapyforstrokerecovery
AT hattorinobutaka pleiotropiceffectsofexosomesasatherapyforstrokerecovery